News Image

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Provided By GlobeNewswire

Last update: Jun 5, 2024

Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise

Read more at globenewswire.com

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (7/25/2025, 9:45:34 AM)

21.36

-0.09 (-0.42%)



Find more stocks in the Stock Screener

Follow ChartMill for more